OR Royalties (OR) Expected to Announce Earnings on Wednesday

OR Royalties (NYSE:ORGet Free Report) is anticipated to post its Q1 2026 results after the market closes on Wednesday, May 6th. Analysts expect the company to announce earnings of $0.34 per share and revenue of $103.50 million for the quarter. Parties may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 7, 2026 at 10:00 AM ET.

OR Royalties (NYSE:ORGet Free Report) last released its quarterly earnings data on Wednesday, February 18th. The basic materials company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.31 by $0.01. The business had revenue of $90.47 million for the quarter, compared to analyst estimates of $90.80 million. OR Royalties had a net margin of 74.30% and a return on equity of 12.41%. On average, analysts expect OR Royalties to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

OR Royalties Trading Down 1.7%

NYSE:OR opened at $36.09 on Tuesday. The firm has a market cap of $6.77 billion, a price-to-earnings ratio of 33.11 and a beta of 0.72. The company’s 50-day moving average is $40.30 and its two-hundred day moving average is $38.17. OR Royalties has a 12-month low of $22.40 and a 12-month high of $48.06.

OR Royalties Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, April 15th. Stockholders of record on Tuesday, March 31st were issued a dividend of $0.055 per share. This represents a $0.22 annualized dividend and a dividend yield of 0.6%. The ex-dividend date was Tuesday, March 31st. OR Royalties’s dividend payout ratio is presently 19.27%.

Institutional Trading of OR Royalties

Institutional investors and hedge funds have recently bought and sold shares of the business. Boothbay Fund Management LLC acquired a new stake in OR Royalties during the 4th quarter worth approximately $450,000. Engineers Gate Manager LP acquired a new stake in OR Royalties in the fourth quarter valued at approximately $397,000. Cetera Investment Advisers grew its position in OR Royalties by 3.5% in the second quarter. Cetera Investment Advisers now owns 13,147 shares of the basic materials company’s stock valued at $337,000 after acquiring an additional 440 shares in the last quarter. Virtus Advisers LLC acquired a new stake in OR Royalties in the third quarter valued at approximately $309,000. Finally, Prelude Capital Management LLC acquired a new stake in OR Royalties in the third quarter valued at approximately $306,000. Institutional investors and hedge funds own 68.52% of the company’s stock.

Wall Street Analysts Forecast Growth

OR has been the topic of several recent analyst reports. Wall Street Zen lowered shares of OR Royalties from a “strong-buy” rating to a “buy” rating in a report on Saturday, April 11th. TD Securities reiterated a “hold” rating on shares of OR Royalties in a report on Monday, February 23rd. Royal Bank Of Canada reiterated an “outperform” rating and set a $56.00 price objective on shares of OR Royalties in a report on Friday, April 10th. Scotiabank increased their price objective on shares of OR Royalties from $41.00 to $51.00 and gave the stock a “sector perform” rating in a report on Monday, January 26th. Finally, Canadian Imperial Bank of Commerce reiterated an “outperform” rating on shares of OR Royalties in a report on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $46.50.

Read Our Latest Report on OR Royalties

OR Royalties Company Profile

(Get Free Report)

OR Royalties PLC (NYSE: OR) is a closed-ended investment company that specializes in acquiring and managing royalty interests in life science and pharmaceutical products. The company provides capital to biotechnology, specialty pharmaceutical and medical device companies in exchange for a share of future sales revenues. By focusing on royalties secured against marketed products, OR Royalties aims to deliver income and growth potential while minimizing the development and commercialization risks typically associated with direct equity stakes.

The company’s core activities include sourcing royalty transactions, structuring bespoke financing solutions and actively monitoring a diversified portfolio of assets.

Recommended Stories

Earnings History for OR Royalties (NYSE:OR)

Receive News & Ratings for OR Royalties Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OR Royalties and related companies with MarketBeat.com's FREE daily email newsletter.